Effect of insulin detemir combined with insulin aspart on islet cell functionin in type 2 diabetes
10.3760/cma.j.issn.1008-6706.2016.09.018
- VernacularTitle:地特胰岛素联合门冬胰岛素对2型糖尿病患者胰岛细胞功能的改善作用
- Author:
Hongliang ZHU
;
Jun ZHOU
;
Qingsen ZHANG
- Publication Type:Journal Article
- Keywords:
Diabetes mellitus,type 2;
Detemir;
Insulin aspart;
Glargine
- From:
Chinese Journal of Primary Medicine and Pharmacy
2016;23(9):1350-1353
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore modification of islet cell function in type 2 diabetes by the treatment of insulin detemir and insulin aspart.Methods A total of 68 patients with diagnosed type 2 diabetes were randomized into two grouops,the control group (insulin glargine combined with insulin aspart)and observation group (insulin detemir combined with insulin aspart),each group had 34 cases.Before and after treatment,fasting insulin and 2 h postprandial insulin,glycated hemoglobin (HbA1c),C peptide and fructosamine (FMN)levels were compared in two groups,and the treatment safety was observed.Results After treatment,fasting insulin and C -peptide levels in the two groups were significantly increased than before treatment(P <0.05 ).In observation group,2 h postprandial insulin level (29.97 ±9.18)mIU /L was significantly higher than before treatment (20.79 ±7.49)mIU /L(t =4.52,P =0.00), which was better than the control group (24.67 ±7.69)mIU /L,the difference was significant (t =2.58,P =0.01). After treatment,postprandial 2h C peptide levels in the two groups had no significant differences compared with before treatment (P >0.05).In the observation group,except for 2h postprandial insulin levels,other indicators had no significant differences compared with the control group (P >0.05 ).After treatment,FMN and HbA1c in the two groups decreased significantly compared with before treatment(P <0.05 ),but there was no significant difference between the two groups (P >0.05).During treatment,both two groups observed hypoglycemia,but there were no severe adverse reactions.Conclusion The clinical application of insulin detemir combined with insulin aspart in the treatment of type 2 diabetes can significantly improve the insulin -producing cells and accelerate functional recovery, and the clinical effect is better than the united aspart insulin glargine,with no significant adverse reactions,it can be recommended as a clinical type 2 diabetes treatment drug of choice.
